Monocyte chemoattractant protein-1 and atherosclerosis: Is there room for an additional biomarker?

Clinica Chimica Acta

Volumn 383, Issue 1-2, 2007, Pages 21-29

  Coll, Blai ^a   Alonso Villaverde, Carlos ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

Author keywords

Arteriosclerosis; Biomarker; Inflammation; MCD 1

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; INTERLEUKIN 1; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD LEVEL; CCL2 GENE; DISEASE COURSE; GENE; HUMAN; INFLAMMATORY CELL; INFLAMMATORY DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; THROMBOSIS;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CHEMOKINE CCL2; HUMANS; RECEPTORS, CHEMOKINE; RISK FACTORS;

ANIMALIA;

EID: 34347383594     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2007.04.019     Document Type: Review

References (108)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 14 (1999) 115-126
2. Stoll G., and Bendszus M. Inflammation and atherosclerosis: novel insights into plaque formation and destabilization. Stroke 37 (2006) 1923-1932
3. Cipollone F., Marini M., Fazia M., et al. Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21 (2001) 327-334
4. Oshima S., Ogawa H., Hokimoto S., et al. Plasma monocyte chemoattractant protein-1 antigen levels and the risk of restenosis after coronary stent implantation. Jpn Circ J 65 (2001) 261-264
5. Hokimoto S., Ogawa H., Saito T., et al. Increased plasma antigen levels of monocyte chemoattractant protein-1 in patients with restenosis after percutaneous transluminal coronary angioplasty. Jpn Circ J 64 (2000) 831-834
6. Hognestad A., Endresen K., Wergeland R., et al. Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 24 (2005) 1026-1032
7. Reape T.J., and Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 147 (1999) 213-225
8. Laberge M.A., Moore K.J., and Freeman M.W. Atherosclerosis and innate immune signaling. Ann Med 37 (2005) 130-140
9. Kher N., and Marsh J.D. Pathobiology of atherosclerosis - a brief review. Semin Thromb Hemost 30 (2004) 665-672
10. Gerard C., and Rollins B.J. Chemokines and disease. Nat Immunol 2 (2001) 108-115
11. Rollins B.J. Chemokines. Blood 90 (1997) 909-928
12. Leonard E.J., and Yoshimura T. Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11 (1990) 97-101
13. Jaffer F.A., Libby P., and Weissleder R. Molecular and cellular imaging of atherosclerosis: emerging applications. J Am Coll Cardiol 47 (2006) 1328-1338
14. Fuster V., Badimon J.J., and Badimon L. Clinical-pathological correlations of coronary disease progression and regression. Circulation 86 (1992) III1-III11
15. Rollins B.J. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 2 (1996) 198-204
16. Ikeda U., Matsui K., Murakami Y., and Shimada K. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 25 (2002) 143-147
17. Yla-Herttuala S., Lipton B.A., Rosenfeld M.E., et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci 88 (1991) 5252-5256
18. Wilcox J.N., Nelken N.A., Coughlin S.R., Gordon D., and Schall T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J Atheroscler Thromb 1 (1994) S10-S13
19. Capers IV Q., Alexander R.W., Lou P., et al. Monocyte chemoattractant protein-1 expression in aortic tissues of hypertensive rats. Hypertension 30 (1997) 1397-1402
20. Hamilton T.A., Major J.A., and Chisolm G.M. The effects of oxidized low density lipoproteins on inducible mouse macrophage gene expression are gene and stimulus dependent. J Clin Invest 95 (1995) 2020-2027
21. Lukacs N.W., Strieter R.M., Elner V., Evanoff H.L., Burdick M.D., and Kunkel S.L. Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood 86 (1995) 2767-2773
22. Walch L., Massade L., Dufilho M., Brunet A., and Rendu F. Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 187 (2006) 285-291
23. 2, and iron are required for TNF-alpha-induced MCP-1 gene expression in endothelial cells: role of Rac1 and NADPH oxidase. Am J Physiol Heart Circ Physiol 286 (2004) H1001-H1007
24. Teferedegne B., Green M.R., Guo Z., and Boss J.M. Mechanism of action of a distal NF-kappa B-dependent enhancer. Mol Cell Biol 26 (2006) 5759-5770
25. Sato Y., Nishio Y., Sekine O., et al. Increased expression of CCAAT/enhancer binding protein-beta and -delta and monocyte chemoattractant protein-1 genes in aortas from hyperinsulinaemic rats. Diabetologia 50 (2007) 481-489
26. Abraham S., Sweet T., Sawaya B.E., Rappaport J., Khalili K., and Amini S. Cooperative interaction of C/EBP beta and Tat modulates MCP-1 gene transcription in astrocytes. J Neuroimmunol 160 (2005) 219-227
27. Morrison R.F., and Farmer S.R. Insights into the transcriptional control of adipocyte differentiation. J Cell Biochem Suppl 32-33 (1999) 59-67
28. Kodama K., Nishio Y., Sekine O., et al. Bidirectional regulation of monocyte chemoattractant protein-1 gene at distinct sites of its promoter by nitric oxide in vascular smooth muscle cells. Am J Physiol Cell Physiol 289 (2005) C582-C590
29. Qiao J.H., Tripathi J., Mishra N.K., et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am J Pathol 150 (1997) 1687-1699
30. Rollins B.J., Stier P., Ernst T., and Wong G.G. The human homolog of the JE gene encodes a monocyte secretory protein. Mol Cell Biol 9 (1989) 4687-4695
31. Boring L., Gosling J., Chensue S.W., et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 100 (1997) 2552-2561
32. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
33. Dawson T.C., Kuziel W.A., Osahar T.A., and Maeda N. Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 143 (1999) 205-211
34. Gu L., Okada Y., Clinton S.K., et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 2 (1998) 275-281
35. Gosling J., Slaymaker S., Gu L., et al. MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 103 (1999) 773-778
36. Roque M., Kim W.J., Gazdoin M., et al. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol 22 (2002) 554-559
37. Aiello R.J., Bourassa P.A., Lindsey S., et al. Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 19 (1999) 1518-1525
38. Sakamoto T., Ishibashi T., Sakamoto N., et al. Endogenous NO blockade enhances tissue factor expression via increased Ca2+ influx through MCP-1 in endothelial cells by monocyte adhesion. Arterioscler Thromb Vasc Biol 25 (2005) 2005-2011
39. Toba H., Nakagawa Y., Miki S., et al. Calcium channel blockades exhibit anti-inflammatory and antioxidative effects by augmentation of endothelial nitric oxide synthase and the inhibition of angiotensin converting enzyme in the N(G)-nitro-L-arginine methyl ester-induced hypertensive rat aorta: vasoprotective effects beyond the blood pressure-lowering effects of amlodipine and manidipine. Hypertens Res 28 (2005) 689-700
40. Saji H., Koike M., Yamori T., et al. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. Cancer 92 (2001) 1085-1091
41. Ma J., Wang Q., Fei T., Han J.D., and Chen Y.G. MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. Blood 109 (2007) 987-994
42. Schepers A., Eefting D., Bonta P.I., et al. Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 26 (2006) 2063-2069
43. Lee P.C., Ho I.C., and Lee T.C. Oxidative stress mediates sodium arsenite-induced expression of heme oxygenase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxicol Sci 85 (2005) 541-550
44. Egashira K., Koyanagi M., Kitamoto S., et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesis. FASEB J 14 (2000) 1974-1978
45. Ni W., Egashira K., Kitamoto S., et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103 (2001) 2096-2101
46. Inoue S., Egashira K., Ni W., et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106 (2002) 2700-2706
47. Kitamoto S., and Egashira K. Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. J Atheroscler Thromb 9 (2002) 261-265
48. Kitamoto S., Nakano K., Hirouchi Y., et al. Cholesterol-lowering independent regression and stabilization of atherosclerotic lesions by pravastatin and by antimonocyte chemoattractant protein-1 therapy in nonhuman primates. Arterioscler Thromb Vasc Biol 24 (2004) 1522-1528
49. Saiura A., Sata M., Hiasa K., et al. Antimonocyte chemoattractant protein-1 gene therapy attenuates graft vasculopathy. Arterioscler Thromb Vasc Biol 24 (2004) 1886-1890
50. Usui M., Egashira K., Ohtani K., et al. Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 16 (2002) 1838-1840
51. Yoshii T., Iwai M., Li Z., et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidative stress actions. Hypertens Res 29 (2006) 457-466
52. Grainger D.J., and Reckless J. Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo. Biochem Pharmacol 65 (2003) 1027-1034
53. Han K.H., Han K.O., Green S.R., and Quehenberger O. Expression of the monocyte chemoattractant protein-1 receptor CCR2 is increased in hypercholesterolemia. Differential effects of plasma lipoproteins on monocytes function. J Lipid Res 40 (1999) 1053-1063
54. Tous M., Ferre N., Rull A., et al. Dietary cholesterol and differential monocyte chemoattractant protein-1 gene expression in aorta and liver of apo E-deficient mice. Biochem Biophys Res Commun 340 (2006) 1078-1084
55. Kanda H., Tateya S., Tamori Y., et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest 116 (2006) 1494-1505
56. Sartipy P., and Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 100 (2003) 7265-7270
57. Weisberg S.P., Hunter D., Huber R., et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 116 (2006) 115-124
58. Kim C.S., Park H.S., Kawada T., et al. Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30 (2006) 1347-1355
59. Malavazos A.E., Cereda E., Morricone L., Coman C., Corsi M.M., and Ambrosi B. Monocyte chemoattractant protein 1: a possible link between visceral adipose tissue-associated inflammation and subclinical echocardiographic abnormalities in uncomplicated obesity. Eur J Endocrinol 153 (2005) 871-877
60. Cancello R., Henegar C., Viguerie N., et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54 (2005) 2277-2286
61. Coll B., Parra S., Alonso-Villaverde C., et al. HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine 34 (2006) 51-55
62. Inadera H., Egashira K., Takemoto M., Ouchi Y., and Matsushima K. Increase in circulating levels of monocyte chemoattractant protein-1 with aging. J Interferon Cytokine Res 19 (1999) 1179-1182
63. Joven J., Coll B., Tous M., et al. The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis. Clin Chim Acta 368 (2006) 114-119
64. Park I.W., Wang J.F., and Groopman J.E. HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood 97 (2001) 352-358
65. Monteiro de S., Almeida S., Letendre J., Zimmerman D., Lazzaretto A., and McCutchan R. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol 169 (2005) 144-152
66. Chang L., Ernst T., St Hillaire C., and Conant K. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Antivir Ther 9 (2004) 431-440
67. McDermott D.H., Yang Q., Kathiresan S., et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation 112 (2005) 1113-1120
68. Elvin S.J., Williamson E.D., Scott J.C., et al. Evolutionary genetics: ambiguous role of CCR5 in Y. pestis infection. Nature 430 (2004) 417
69. Szalai C., Duba J., Prohaszka Z., et al. Involvement of polymorphisms in the chemokine system in the susceptibility for coronary artery disease (CAD). Coincidence of elevated Lp(a) and MCP-1-2518 G/G genotype in CAD patients. Atherosclerosis 158 (2001) 233-239
70. Heinecke J.W. Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander. J Exp Med 203 (2006) 813-816
71. Sonoki K., Yoshinari M., Iwase M., et al. Glycoxidized low-density lipoprotein enhances monocyte chemoattractant protein-1 mRNA expression in human umbilical vein endothelial cells: relation to lysophosphatidylcholine contents and inhibition by nitric oxide donor. Metabolism 51 (2002) 1135-1142
72. Wang G.P., Deng Z.D., Ni J., and Qu Z.L. Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudates macrophages. Atherosclerosis 133 (1997) 31-36
73. Mackness B., Hine D., Liu Y., Mastorikou M., and Mackness M. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Biochem Biophys Res Commun 318 (2004) 680-683
74. Zineh I., Luo X., Welder G.J., et al. Modulatory effects of atorvastatin on endothelial cell-derived chemokines, cytokines, and angiogenic factors. Pharmacotherapy 26 (2006) 333-340
75. Han K.H., Ryu J., Hong K.H., et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111 (2005) 1439-1447
76. Xu Z.M., Zhao S.P., Li Q.Z., Nie S., and Zhou H.N. Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 338 (2003) 17-24
77. Kowalski J., Okopien B., Madej A., et al. Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocytes chemoattractant protein-1 secretion in patients with hyperlipidemia. Eur J Clin Pharmacol 59 (2003) 189-193
78. Takebayashi K., Matsumoto S., Wakabayashi S., et al. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia. Metabolism 54 (2005) 1225-1229
79. Troseid M., Lappegard K.T., Claudi T., et al. Effect of monthly atorvastatin and fenofibrate treatment on monocytes chemoattractant protein-1 release in patients with primary mixed dyslipidemia. J Cardiovasc Pharmacol 45 (2005) 314-320
80. Okopien B., Krysiak R., Haberka M., and Herman Z.S. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J 25 (2004) 349-355
81. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
82. Koh K.K., Son J.W., Ahn J.Y., et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension 44 (2004) 180-185
83. Wang G., Wei J., Guan Y., Jin N., Mao J., and Wang X. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces clinical inflammatory responses in type 2 diabetes with coronary artery disease after coronary angioplasty. Metabolism 54 (2005) 590-597
84. Groot P.H., van Stiphout W.A., Krauss X.H., et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 11 (1991) 653-662
85. Coll B., van Wijk J.P., Parra S., et al. Effects of rosiglitazone and metformin on postprandial paraoxonase-1 and monocyte chemoattractant protein-1 in human immunodeficiency virus-infected patients with lipodystrophy. Eur J Pharmacol 544 (2006) 104-110
86. van Wijk J.P., Cabezas M.C., Coll B., Joven J., Rabelink T.J., and de Koning E.J. Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes. Atherosclerosis 186 (2006) 152-159
87. Dragomir E., Tircol M., Manduteanu I., Voinea M., and Simionescu M. Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells. Vascul Pharmacol 44 (2006) 440-449
88. Larrouse M., Bragulat E., Segarra M., Sierra C., Coca A., and de la Sierra A. Increased levels of atherosclerosis markers in salt-sensitive hypertension. Am J Hypertens 19 (2006) 87-93
89. Mine S., Okada Y., Tanikawa T., Kawahara C., Tabata T., and Tanaka Y. Increased expression levels of monocyte CCR2 and monocyte chemoattractant protein-1 in patients with diabetes mellitus. Biochem Biophys Res Commun 344 (2006) 780-785
90. Kim MP, Wahl LM, Yanek LR, Becker DM, Becker LC. A monocyte chemoattractant protein-1 gene polymorphism is associated with occult ischemia in a high-risk asymptomatic population. Atherosclerosis in press [Electronic publication ahead of print].
91. Naghavi M., Falk E., Hecht H.S., et al. For the SHAPE Task Force. From vulnerable plaque to vulnerable patient-Part III: Executive summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force report. Am J Cardiol 98 2A (2006) 2H-15H
92. Alonso-Villaverde C., Coll B., Parra S., et al. Atherosclerosis in patients infected with HIV is influenced by a mutant monocytes chemoattractant protein-1 allele. Circulation 110 (2004) 2204-2209
93. Deo R., Khera A., McGuire D.K., et al. Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 44 (2004) 1812-1818
94. Mosedale D.E., Smith D.J., Aitken S., et al. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis 183 (2005) 268-274
95. Iwai N., Kajimoto K., Kokubo Y., et al. Assessment of genetic effects of polymorphisms in the MCP-1 gene on serum MCP-1 levels and myocardial infarction in Japanese. Circ J 70 (2006) 805-809
96. Pawlak K., Pawlak D., Brzosko S., and Mysliwiec M. Carotid atherosclerosis is associated with enhanced beta-chemokine levels in patients on continuous ambulatory peritoneal dialysis. Atherosclerosis 186 (2006) 146-151
97. de Lemos J.A., Morrow D.A., Sabatine M.S., et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107 (2003) 690-695
98. Martinovic I., Abegunewardene N., Seul M., et al. Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 69 (2005) 1484-1489
99. Herder C., Baumert J., Thorand B., et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc Biol 26 (2006) 2147-2152
100. Arakelyan A., Petrkova J., Hermanova Z., Boyajyan A., Lukl J., and Petrek M. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. Mediators Inflamm 2005 (2005) 175-179
101. Hoogeveen R.C., Morrison A., Boerwinkle E., et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 183 (2005) 301-307
102. Van Mieghem C.A., Bruining N., Schaar J.A., et al. Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology. Int J Cardiovasc Imaging 21 (2005) 425-441
103. Van Mieghem C.A., McFadden E.P., de Feyter P.J., et al. Noninvasive detection of subclinical coronary atherosclerosis coupled with assessment of changes in plaque characteristics using novel invasive imaging modalities: the Integrated Biomarker and Imaging Study (IBIS). J Am Coll Cardiol 47 (2006) 1134-1142
104. Manolio T. Novel risk markers and clinical practice. N Engl J Med 349 (2003) 1587-1589
105. Tsimikas S., Willerson J.T., and Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol 47 (2006) C19-C31
106. Ridker P.M., Rifai N., Rose L., Buring J.E., and Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347 (2002) 1557-1565
107. Charo I.F., and Ransohoff R.M. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 354 (2006) 610-621
108. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006) 515-581